Kura Oncology

What Kura Oncology does

Kura Oncology, Inc. is a commercial-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California (with an additional office in Boston, Massachusetts). The company develops precision medicines for the treatment of solid tumors and blood cancers, with a pipeline organized around two proprietary small-molecule platforms: menin inhibitors that disrupt the menin-KMT2A/MLL protein interaction (lead asset ziftomenib, marketed as KOMZIFTI) and next-generation farnesyl transferase inhibitors (FTIs) including darlifarnib and tipifarnib, designed to overcome treatment resistance in combination regimens. The lead product, KOMZIFTI, is the first and only FDA-approved (November 2025) once-daily oral menin inhibitor for adults with relapsed/refractory NPM1-mutated acute myeloid leukemia, priced at $48,500 per month WAC, and dispensed in the U.S. through specialty pharmacy partner Onco360.

The business model combines direct U.S. commercialization of KOMZIFTI via a field sales force targeting hematologists and oncologists with a global strategic collaboration with Kyowa Kirin (November 2024) covering ex-U.S. development, regulatory, and commercialization of ziftomenib, which delivered $195M in milestone payments to Kura in 2025. Revenue in Q1 2026 was $18.27M (28% below the $25.4M consensus), consisting of a mix of lumpy collaboration revenue and early product sales, with $580.8M in cash, cash equivalents, and short-term investments providing runway into 2027. The pipeline extends ziftomenib into frontline AML (Phase 3 KOMET-017 across 200+ sites; KOMET-007 combinations), darlifarnib into KRAS-mutant solid tumors, renal cell carcinoma, and head and neck cancer in combination with adagrasib and cabozantinib (FIT-001), tipifarnib in PIK3CA-dependent HNSCC (KURRENT-HN), and preclinical KO-7246, a next-generation menin inhibitor in diabetes/cardiometabolic disease.

Kura is publicly traded on NASDAQ under ticker KURA, with a market capitalization of approximately $982M as of May 2026, and is led by founder Troy Wilson, Ph.D., J.D., as President and CEO. The company was founded in 2014, has 101-250 employees, and maintains board oversight from directors with extensive biopharmaceutical commercial-launch experience, including former Kite Pharma (Yescarta launch) and Pharmacyclics (Imbruvica launch) leadership.

Name

Kura Oncology

Legal name

Kura Oncology, Inc.

Website

http://www.kuraoncology.com/

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

251–500 employees

Short description

Kura Oncology is a commercial-stage biopharmaceutical company developing precision small-molecule therapies for cancer, led by FDA-approved KOMZIFTI (ziftomenib) for NPM1-mutated AML and a pipeline of menin inhibitors and farnesyl transferase inhibitors in solid tumor and hematologic indications.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Precision oncology therapeutics
• Targeted cancer therapies
• Menin inhibitors
• Farnesyl transferase inhibitors
• Acute myeloid leukemia treatment

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Revenue - KOMZIFTI (ziftomenib): The company launched commercial sales of KOMZIFTI in the United States following FDA approval in November 2025. The drug generated $2.1 million in net product revenue during its first five weeks of commercial sales in Q4 2025. Pricing is at $48,500 per month wholesale acquisition cost. This represents the company's transition from a clinical-stage to a commercial-stage biotech, with revenue expected to grow as the drug expands into broader AML treatment lines.
2. Collaboration and Milestone Payments - Kyowa Kirin: Under the November 2024 global strategic collaboration agreement with Kyowa Kirin, the company receives milestone payments tied to development and regulatory progress. In 2025, Kura received $195 million in milestone payments including $135 million triggered by rapid FDA approval and $60 million from Phase 3 trial initiations. Additional potential milestones of up to $315 million are anticipated through the collaboration, plus $180 million in additional collaboration payments expected through 2028.
3. Equity Investment and Debt Financing: The company has raised capital through equity investments (e.g., $25 million from Bristol Myers Squibb in November 2022) and debt financing (up to $125 million term loan from Hercules Capital). These financing transactions are designed to fund clinical programs and extend the company's cash runway, with the January 2024 $150 million private placement extending cash runway into 2027.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Kura Oncology is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes precision medicines for solid tumors and blood cancers. Its commercial product KOMZIFTI (ziftomenib) is an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. The pipeline includes darlifarnib (KO-2806), a next-generation farnesyl transferase inhibitor for solid tumor combinations, tipifarnib for HRAS-mutant head and neck cancer, and KO-7246, a next-generation menin inhibitor in preclinical development.

Product overview

Kura Oncology is a commercial-stage biopharmaceutical company developing a pipeline of precision medicines for cancer treatment. The company's lead commercial product is KOMZIFTI (ziftomenib), an FDA-approved once-daily oral menin inhibitor for relapsed or refractory NPM1-mutated AML, which received full FDA approval in November 2025. The development pipeline includes ziftomenib in multiple Phase 1 and Phase 3 registrational trials for frontline AML combinations; darlifarnib (KO-2806), a next-generation farnesyl transferase inhibitor being evaluated in solid tumor combinations including renal cell carcinoma and KRAS-mutant cancers; tipifarnib, an oral FTI in registration-enabling studies for head and neck squamous cell carcinoma; and KO-7246, a next-generation menin inhibitor in preclinical development for diabetes and cardiometabolic disease.

Differentiator

Problem solved

Functional benefit

Brands

• KOMZIFTI: FDA-approved once-daily targeted therapy (ziftomenib) for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.

Products and services

• KOMZIFTI (ziftomenib) KOMZIFTI is an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). It inhibits the interaction between menin and KMT2A/MLL proteins, inducing differentiation of leukemia cells into mature white blood cells. It is the first and only once-daily targeted therapy for this indication, with no boxed warnings. Priced at $48,500 per month wholesale acquisition cost and dispensed through specialty pharmacy partner Onco360.

Quantifiable outcome

• 96% composite complete remission rate in NPM1-mutant AML patients treated with ziftomenib plus 7+3 chemotherapy
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Onco360coreChannel Partner/ Reseller/ Distributor · 17 November 2025Onco360 was selected as the national specialty pharmacy partner for dispensing KOMZIFTI (ziftomenib) to adult AML patients with NPM1 mutations in the United States. As a leading independent specialty pharmacy, Onco360 handles the complex distribution, reimbursement support, and patient services required for high-cost oncology therapeutics.
• Kyowa KirinflagshipStrategic or Co-development Partner · 1 November 2024In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. to develop and commercialize ziftomenib for acute myeloid leukemia and other hematologic malignancies. Kyowa Kirin leads development, regulatory, and commercialization activities outside the United States, while Kura retains US rights. The collaboration includes milestone payments of up to $315 million plus royalties, with Kyowa Kirin providing significant financial support for the global development program. A Japanese Phase 2 registration-directed trial was initiated in 2026.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Pfizer operates a broad hematology/oncology portfolio and is developing menin inhibitor and KRAS-directed programs that directly intersect with Kura's core and pipeline indications.
• AbbVie: AbbVie acquired ImmunoGen for ADC-based oncology assets and has a broad hematology/oncology portfolio that competes for institutional AML and solid tumor accounts, while also partnering with Kura through prior clinical and equity relationships.
• BeiGene: BeiGene is a global hematology/oncology commercial-stage company (Brukinsa, tislelizumab) targeting overlapping precision oncology customer segments and pipeline indications as Kura.
• Bristol Myers Squibb: BMS is a Kura equity investor ($25M in 2022) and a major oncology franchise holder (Reblozyl in MDS, AML combination studies), providing both a commercial benchmark and a financial sponsor relationship.
• Daiichi Sankyo: Daiichi Sankyo is a global oncology leader (ADC franchise including Enhertu) with active AML and hematology programs, competing for the same specialty hematology and precision oncology accounts.

Direct peers

• Jazz Pharmaceuticals: Jazz markets Vyxeos (CPX-351) and other hematology/oncology therapies, directly overlapping with Kura's AML commercial focus and specialty hematology customer base.
• Agios Pharmaceuticals: Agios commercializes Tibsovo (ivosidenib) for IDH1-mutated AML and other hematology/oncology indications, overlapping with Kura's targeted-therapy AML franchise and specialty distribution channels.
• Astellas Pharma: Astellas markets Xospata (gilteritinib) for FLT3-mutated relapsed/refractory AML, targeting the same academic hematologist community and competing for AML combination and second-line share.
• Syndax Pharmaceuticals: Syndax is developing revumenib, a competing menin inhibitor for NPM1-mutant and KMT2A-rearranged AML, making it the most direct U.S. commercial-stage competitor to Kura's KOMZIFTI in the same molecularly defined AML niche.

Others

• Kyowa Kirin: Kyowa Kirin is Kura's global strategic partner for ex-US development and commercialization of ziftomenib and a financial counterparty via milestone payments — adjacent ecosystem rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/kuraoncology
• LinkedInlinkedin.com/company/kura-oncology-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds12 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kura Oncology